3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Phase 4
3
Phase NA
2
Phase 2
2
Phase EARLY_PHASE1
1
Status
Withdrawn
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Genitourinary
1
Classical hematology
1
Conditions
Colorectal Neoplasms
8
Breast Neoplasms
7
Polycythemia Vera
5
Venous Thromboembolism
3
Melanoma
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Tobacco Use Disorder
2
Thrombocythemia, Essential
2
Smoking Cessation
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
Neoplastic Cells, Circulating
2
Neoplasms
2
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Multiple Myeloma
2
Lung Neoplasms
2
Barrett Esophagus
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Tuberous Sclerosis
1
Thromboembolism
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Seizures
1
Salivary Gland Neoplasms
1
Recurrence
1
Primary Myelofibrosis
1
Precancerous Conditions
1
Interventions
Gemcitabine
53
Bevacizumab
52
Cyclophosphamide
49
Docetaxel
42
Carboplatin
40
pembrolizumab
37
Paclitaxel
36
Fluorouracil
36
Cisplatin
35
Radiotherapy
31
Oxaliplatin
31
Capecitabine
29
Irinotecan
28
Dexamethasone
27
Leucovorin
25
Cetuximab
25
Nivolumab
24
Doxorubicin
22
Drug Therapy
21
Erlotinib Hydrochloride
20
Pemetrexed
19
durvalumab
18
trametinib
17
fludarabine
16
atezolizumab
16
Trastuzumab
16
Sunitinib
16
Rituximab
16
Prednisone
16
Sorafenib
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms
×
Aspirin
×
Clear all
NCT06866964
2026-02-02
ASPIRE
Wake Forest University Health Sciences
Phase 2
Recruiting
35 enrolled
NCT02323516
2015-12-08
ASPIDIA
Centre Francois Baclesse
Phase 2
Withdrawn